1. Home
  2. BCG vs MDXH Comparison

BCG vs MDXH Comparison

Compare BCG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.07

Market Cap

21.6M

Sector

N/A

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.19

Market Cap

18.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
MDXH
Founded
2016
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
18.5M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
BCG
MDXH
Price
$1.07
$0.19
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $1.13
AVG Volume (30 Days)
16.2K
★ 1.3M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 112.50
N/A
EPS
★ 0.08
N/A
Revenue
★ $187,144,000.00
N/A
Revenue This Year
N/A
$5.10
Revenue Next Year
N/A
$13.22
P/E Ratio
$13.50
★ N/A
Revenue Growth
★ 10.80
N/A
52 Week Low
$0.95
$0.17
52 Week High
$3.44
$5.33

Technical Indicators

Market Signals
Indicator
BCG
MDXH
Relative Strength Index (RSI) 46.11 23.19
Support Level $0.95 N/A
Resistance Level $1.67 $0.66
Average True Range (ATR) 0.04 0.05
MACD 0.02 -0.04
Stochastic Oscillator 75.06 2.27

Price Performance

Historical Comparison
BCG
MDXH

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: